• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

    5/14/25 6:59:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos and glare.

    "Zenlens CHROMA HOA is a high-quality, customizable lens that fills a critical gap in scleral lens vision correction, especially for patients with complex corneal irregularities," said Yang Yang, president, Global Vision Care, Bausch + Lomb. "Eye care professionals in the U.S. now have a new solution for patients that previously had limited options to improve vision quality."

    HOA correction starts with a secure lens fit1, which can be achieved through proprietary Zenlens technologies, including SmartCurve™ and Bi-Elevation™. Once lens stability is secured, custom HOA correction is applied to the lens to effectively reduce higher-order aberrations and enhance vision by minimizing blurring and distortion.

    "For years, I've had patients who struggle with visual distortions caused by higher-order aberrations, and there was little I could do beyond basic correction," said Jason Jedlicka, OD, chief of cornea and contact lens service and clinical professor, Indiana University School of Optometry. "With Zenlens CHROMA HOA, I can offer a level of precision that wasn't previously possible, and my patients can experience sharper vision and improved clarity, which has a significant impact on their quality of life."

    Bausch + Lomb is collaborating with Advance Medical and OVITZ® to help eye care professionals integrate Zenlens CHROMA HOA into their practices. Advance Medical's FocalPoints® software platform – a leading platform for specialty lens manufacturing – enables seamless and precise production of the Zenlens CHROMA HOA design. OVITZ, the first company to develop an aberrometry system specifically for HOA correction, is providing its latest device, the xwave aberrometer.

    For more information on Zenlens CHROMA HOA, visit www.bauschsvp.com/lenses/zenlens.

    Important Safety Information for Gas Permeable and Customized Soft Contact Lenses

    WARNINGS:

    Patients should be advised of the following warnings pertaining to contact lens wear:

    • Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their eyecare practitioner's directions and all labeling instructions for proper use of lenses and lens care products, including the lens case. Eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.
    • Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. Clinical studies have shown that the risk of serious adverse reactions is increased when daily wear lenses are worn overnight.
    • Studies have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
    • If a patient experiences eye discomfort, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eyecare practitioner.

    CONTRAINDICATIONS:

    Do not use when any of the following conditions exist:

    • Acute or subacute inflammation or infection of the anterior chamber of the eye.
    • Any eye disease, injury or abnormality, other than keratoconus, PMD, that affects the cornea, conjunctiva or eyelids
    • Severe insufficiency of lacrimal secretion (dry eye)
    • Corneal hypoesthesia (reduced sensitivity), if not aphakic
    • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses
    • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or using contact lens solutions
    • Allergy to any ingredient in a solution which is to be used to care for contact lenses
    • Any active corneal infection (bacterial, fungal or viral)
    • Red or irritated eyes

    ADVERSE EFFECTS:

    The following problems may occur with the use of contact lenses:

    • Eyes stinging, burning, itching, irritation or other eye pain
    • Comfort is less than when the lens was first placed on the eye
    • Feeling of something in the eye such as a foreign body, scratched area
    • Excessive watering (tearing) of the eye
    • Unusual eye secretions
    • Redness of the eyes
    • Reduced sharpness of vision (poor visual acuity)
    • Blurred vision, rainbows, or halos around objects
    • Sensitivity to light (photophobia)
    • Dry eyes

    About HOAs

    HOAs are complex irregularities in the eye's lens or cornea that can significantly impact visual clarity. They result from factors such as irregularities in the corneal shape, scarring, previous eye surgeries, large pupils or certain medical conditions affecting the eye, such as keratoconus or other corneal dystrophies. They can also be induced by the aging process or from changes in the eye's internal structures. Patients who have HOAs can experience symptoms such as blurred vision, halos, glare and difficulty seeing in low light conditions such as driving at night.

    About Bausch + Lomb

    Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

    Reference

    1. Shah P, Gidosh N. Awesome vision after aberration control: the future of scleral lens optics. Poster presented at: The Global Specialty Lens Symposium; January 17-20, 2024; Las Vegas, NV.

    FocalPoints is a trademark of Advanced Medical.

    All other product/brand names are trademarks of the respective owners.

    © 2025 Bausch + Lomb.

    ALZN.0026.USA.25

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250514394244/en/

    Media:

    Kristy Marks

    [email protected]

    (908) 927-0683

    Get the next $BLCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $BLCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

      5/21/25 4:30:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

      Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

      2/28/24 8:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

      Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

      2/21/24 7:00:00 AM ET
      $BLCO
      $EBS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BLCO
    Financials

    Live finance-specific insights

    See more
    • Bausch + Lomb Announces First-Quarter 2025 Results

      Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning

      4/30/25 6:57:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date:     Wednesday, April 30, 2025   Time:     8 a.m. ET   Webcast:     https://www.webcaster4.com/Webcast/Page/2883/51713   Participant Event Dial-in:     +

      3/26/25 7:45:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

      Fourth-Quarter 2024 Financial Results Revenue of $1.280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results Revenue of $4.791 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $317 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $878 Million Revenue Grew 16% as Reported and 17% on a Constant Currency1 Basis Compared to the Full Year of 2023, with Growth Across All Segments Baus

      2/19/25 6:58:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/27/25 8:16:24 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      8/7/24 5:29:48 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have launched an offering of €600 million aggregate principal amount of senior secured floating rate notes ("Notes"). In connection with the Notes offering, the company has also launched a partial refinancing of its credit agreement, whereby the company intends to obtain a $2.2 billion new term B loan facility (the "New Term B Loan Facility") and a new $800 million revolving credit facility (the

      6/10/25 8:48:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

      Blink Nourish and Blink Boost are now available at most U.S. national retailers, including Walmart, Target, CVS, Walgreens and Amazon Blink Nourish is the first and only vitamin-enriched preservative-free eye drop designed to replenish and rebalance the tear film Blink Boost's formula is pH-balanced to match healthy tears, making it comfortable when applied Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to

      6/4/25 6:59:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chief Financial Officer Sam Eldessouky is scheduled to participate in the 2025 Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 7:35 a.m. ET. A live webcast of the conference will be available on the Investor Relations section of the Bausch + Lomb website. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses,

      5/22/25 7:30:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Bausch + Lomb with a new price target

      H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      5/2/25 7:51:06 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously

      3/28/25 8:14:16 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Citigroup with a new price target

      Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously

      12/11/24 7:25:38 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch + Lomb Corporation

      SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

      2/14/23 5:14:30 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BLCO
    SEC Filings

    See more
    • Director Von Eschenbach Andrew C. was granted 20,338 shares, increasing direct ownership by 49% to 62,086 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:11:49 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Ross Thomas W. Sr. was granted 20,338 shares, increasing direct ownership by 51% to 60,391 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:10:50 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Robertson Russel C was granted 20,338 shares, increasing direct ownership by 46% to 64,914 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:09:56 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/10/25 9:05:43 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form SD filed by Bausch + Lomb Corporation

      SD - Bausch & Lomb Corp (0001860742) (Filer)

      5/30/25 4:14:06 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form 8-K filed by Bausch + Lomb Corporation

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      5/21/25 4:36:14 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care